EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ATF4 , ZIK1 , and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer

Angelo Borges de Melo Neto, Fábio Ribeiro Queiroz, Carolina Pereira de Souza Melo, Bruna Custódio Dias Duarte iD, Jorge Gomes Goulart Ferreira, Izabela Ferreira Gontijo de Amorim, Laurence Rodrigues do Amaral, Pedro Luiz Lima Bertarini, Telma Maria Rossi de Figueiredo Franco, Andréa Teixeira de Carvalho iD, Olindo Assis Martins-Filho, Wander de Jesus Jeremias und 3 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Angelo Borges de Melo Neto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Activating Transcription Factor 4, Chemoradiotherapy, Transcriptome. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Brazilian Ministry of Health, Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow‐up treatment response in CC patients.

Methods

Samples of non‐stem CC cells selected by Fluorescence‐activated Cell Sorting from 21 Responders and 10 Non‐responder patients, who attended the Mario Penna Institute (Belo Horizonte—Brazil) from August 2017 to May 2018, and submitted to Next‐generation RNA sequencing, were analyzed to evaluate differential gene expression profiles between both groups. Machine Learning and statistical analyses were performed to identify a signature related to clinical outcomes.

Results

2670 Differentially expressed genes (DEGs) with log 2 FoldChange ≤ −1 or ≥ 1 and adjusted p ‐value ≤ 0.05 were found. Of these, 1591 were protein‐coding, but only 8 were considered relevant based on machine‐learning and statistical analyses for classifying treatment response. However, only PNMA3 and ZIK1 were markedly upregulated in non‐responder patients. Among the genes upregulated in Responder patients, only ATF4 and ATP1B3 were identified by machine‐learning analysis. On the other hand, only ATF4 , PNMA3 , and ZIK1 were associated in network interactions, more specifically to apoptosis pathways, and the differential expression of ATF4 and PNMA3 occurred exclusively in cervical cancer non‐stem cells, in the presence of ZIK1 .

Conclusions

We propose that upregulation of PNMA3 and downregulation of ATF4 , specifically in cervical cancer non‐stem cells, is associated with upregulation of ZIK1 and with resistance to apoptosis and chemoradiotherapy. Therefore, suggesting that these genes may serve as potential signatures for CC prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsActivating Transcription Factor 4ChemoradiotherapyTranscriptomeHumansFemaleGene Expression Regulation, NeoplasticPrognosisGene Expression ProfilingBiomarkers, Tumor

Stichwörter der Autor:innen

ATF4PNMA3ZIK1cervical cancerchemoradiotherapy resistance

Substanzen

Activating Transcription Factor 4ATF4 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.
  • Laboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
  • Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Belo Horizonte, Brazil.
  • Laboratório de Farmacologia Experimental, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
  • Programa de Pós-graduação em Ciências Morfofuncionais, Universidade Federal de São João D'El Rei, São João D'El Rei, Brazil.

ORCID-Profile: Bruna Custódio Dias Duarte, Andréa Teixeira de Carvalho, Letícia da Conceição Braga

Förderung

  • Brazilian Ministry of Health
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Rede Mineira de Pesquisa Translacional em Oncologia
  • Ministério da Saúde

Zitieren

APA

de Melo Neto, A. B., Queiroz, F. R., de Souza Melo, C. P., Duarte, B. C. D., Ferreira, J. G. G., de Amorim, I. F. G., do Amaral, L. R., Bertarini, P. L. L., de Figueiredo Franco, T. M. R., de Carvalho, A. T., Martins-Filho, O. A., de Jesus Jeremias, W., da Conceição Braga, L., de Oliveira Salles, P. G., & de Souza Gomes, M. (2026). ATF4 , ZIK1 , and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.72053

Vancouver

de Melo Neto AB, Queiroz FR, de Souza Melo CP, Duarte BCD, Ferreira JGG, de Amorim IFG, et al. ATF4 , ZIK1 , and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.72053

BibTeX
@article{deMeloNeto2026,
  author = {de Melo Neto, Angelo Borges and Queiroz, Fábio Ribeiro and de Souza Melo, Carolina Pereira and Duarte, Bruna Custódio Dias and Ferreira, Jorge Gomes Goulart and de Amorim, Izabela Ferreira Gontijo and do Amaral, Laurence Rodrigues and Bertarini, Pedro Luiz Lima and de Figueiredo Franco, Telma Maria Rossi and de Carvalho, Andréa Teixeira and Martins-Filho, Olindo Assis and de Jesus Jeremias, Wander and da Conceição Braga, Letícia and de Oliveira Salles, Paulo Guilherme and de Souza Gomes, Matheus},
  title = {ATF4 , ZIK1 , and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72053}
}
Kostenlos starten →